Study wrapper · #1388
Tirzepatide and the Incidence of Atrial Fibrillation in Adults With Overweight or Obesity: An Updated Meta-Analysis of Randomized Controlled Trials.
Mansouri ES, Queiroga F, Barbosa LM, et al. Journal of the American Heart Association. 2026.
DOI: 10.1161/jaha.125.044249PubMed: 42714458
Editor's note
Bayesian rare-event methods are the right tool here, and the credible intervals tell the story: the atrial-fibrillation estimate (OR 2.20, 95% CrI 0.81-6.75) is compatible with anything from no effect to a large one. The any-arrhythmia signal just crosses significance and warrants monitoring rather than alarm. Event counts this low mean longer trials and pharmacovigilance data will settle the question, not this analysis — a point the authors themselves make.
Plain-language abstract
Pooling 10 randomized trials with about 6,500 participants, tirzepatide was not clearly linked to atrial fibrillation, but the odds of experiencing any arrhythmia were roughly 1.8-fold higher — with so few events overall that the estimates remain uncertain.
Related coverage
Weak / none
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economicsn=——2026
Mixed
Sleeve gastrectomy versus tirzepatide to improve survival among patients with stage 5 CKD: A Markov decision analysis.
American journal of surgeryn=——2026
Mixed
Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.
Journal of chromatography. An=——2026